144 related articles for article (PubMed ID: 10726623)
21. CA 125 in biological fluids.
Molina R; Filella X; Jo J; Agusti C; Ballesta AM
Int J Biol Markers; 1998; 13(4):224-30. PubMed ID: 10228906
[TBL] [Abstract][Full Text] [Related]
22. Can we preoperatively risk stratify ovarian masses for malignancy?
Oltmann SC; Garcia N; Barber R; Huang R; Hicks B; Fischer A
J Pediatr Surg; 2010 Jan; 45(1):130-4. PubMed ID: 20105592
[TBL] [Abstract][Full Text] [Related]
23. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
24. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma.
Saygili U; Guclu S; Uslu T; Erten O; Dogan E
Int J Gynecol Cancer; 2002; 12(5):438-42. PubMed ID: 12366659
[TBL] [Abstract][Full Text] [Related]
25. Gynecological surveillance in high risk women.
Dilley J; Gentry-Maharaj A; Menon U
Minerva Ginecol; 2016 Oct; 68(5):497-508. PubMed ID: 26930388
[TBL] [Abstract][Full Text] [Related]
26. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
27. [Retrospective study of 167 ovarian tumors].
Chechia A; Kaubâa A; Bahri N; Terras K; Makhlouf T
Tunis Med; 1999 Nov; 77(11):551-7. PubMed ID: 10730141
[TBL] [Abstract][Full Text] [Related]
28. [-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-].
Nagele E; Kurz C; Speiser P; Vavra N; Sevelda P
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):79-82. PubMed ID: 8647363
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
30. Lights and shadows of the tumoral marker CA-125 in ovarian cancer.
Sánchez Muñoz A; González Martín A; Mendiola Fernández C
Clin Transl Oncol; 2008 Aug; 10(8):449-52. PubMed ID: 18667373
[No Abstract] [Full Text] [Related]
31. Differentiation between borderline and benign ovarian tumors: combined analysis of MRI with tumor markers for large cystic masses (≥5 cm).
Park SY; Oh YT; Jung DC
Acta Radiol; 2016 May; 57(5):633-9. PubMed ID: 26231948
[TBL] [Abstract][Full Text] [Related]
32. Is early detection of ovarian cancer possible?
Schwartz PE; Taylor KJ
Ann Med; 1995 Oct; 27(5):519-28. PubMed ID: 8541026
[TBL] [Abstract][Full Text] [Related]
33. Preoperative evaluation of ovarian masses: ultrasound and biochemical screening.
Piccioni MG; Fabiani C; Fattouche V; Furano S; Melluso J; Sabelli V
Clin Exp Obstet Gynecol; 2003; 30(4):217-9. PubMed ID: 14664416
[TBL] [Abstract][Full Text] [Related]
34. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.
Riedinger JM; Bonnetain F; Basuyau JP; Eche N; Larbre H; Dalifard I; Wafflart J; Ricolleau G; Pichon MF
Ann Oncol; 2007 May; 18(5):881-5. PubMed ID: 17301071
[TBL] [Abstract][Full Text] [Related]
35. [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
Grabiec M; Nowicki P; Walentowicz M; Greźlikowska U; Mierzwa T; Chmielewska W
Ginekol Pol; 2005 May; 76(5):371-6. PubMed ID: 16145856
[TBL] [Abstract][Full Text] [Related]
36. [Preoperative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings. CA 125 in serum and menopausal status].
Hagen B; Tingulstad S; Onsrud M; Moen M; Kiserud T; Eik-Nes S; Halvorsen T; Nustad K
Tidsskr Nor Laegeforen; 1995 Mar; 115(7):820-2. PubMed ID: 7701488
[TBL] [Abstract][Full Text] [Related]
37. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
38. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
Berek JS; Bast RC
Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
[TBL] [Abstract][Full Text] [Related]
40. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
